No surprises here. We were aware of the massive costs coming from staff. I wasn't expecting revenue to exceed previous years, thought it would be significant down, but i'll take that.
Key point here which i was looking for about cutting costs
Recognising continued procurement delays across both the ANZ and UK markets and the need to appropriately balance
future growth potential against the current cost base, in Q3 Alcidion will implement annualised costs savings, primarily
via the reduction of staff costs, of approximately $6.4M, resulting from:
• $2.4M of annualised cost savings realised in the first half of the year; and
• $4.0M of annualised cost savings, to be implemented during the third quarter
Given the various timings for the cost savings, coupled with restructure and redundancy costs, Alcidion will realise
approximately $2.2M of the proposed costs saving in FY24.
- Forums
- ASX - By Stock
- Ann: Alcidion FY24 Appendix 4D and Half Year Report
ALC
alcidion group limited
Add to My Watchlist
5.00%
!
10.5¢

No surprises here. We were aware of the massive costs coming...
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
10.5¢ |
Change
0.005(5.00%) |
Mkt cap ! $134.2M |
Open | High | Low | Value | Volume |
10.0¢ | 10.5¢ | 10.0¢ | $2.352K | 23.00K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
22 | 1377042 | 10.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.5¢ | 501976 | 4 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
22 | 1377042 | 0.100 |
2 | 308000 | 0.099 |
3 | 215000 | 0.098 |
1 | 300000 | 0.097 |
2 | 208000 | 0.096 |
Price($) | Vol. | No. |
---|---|---|
0.105 | 501976 | 4 |
0.110 | 2201616 | 30 |
0.115 | 832192 | 14 |
0.120 | 1003457 | 11 |
0.125 | 2372221 | 9 |
Last trade - 12.49pm 04/07/2025 (20 minute delay) ? |
Featured News
ALC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Dr Michael Thurn, CEO & MD
Dr Michael Thurn
CEO & MD
SPONSORED BY The Market Online